Form D · Other Technology
GX Molecular Inc.
Cambridge, X0 · CIK 0001866545
Offering snapshot reported Sep 20, 2022 · SEC filing
- Reported sold
- $14.5M Offering amount: $20M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 7, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 20, 2022 | Initial | $14,546,228 | No comparison | 17 | SEC filing |
| Jun 10, 2021 | Initial | $2,225,000 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-459301
Actual Total Offering Amount: $20,016,226.49; Actual Total Amount Sold: $14,546,227.18; Actual Total Amount Remaining to be Sold: $5,469,999.31
Source: Form D, filed Sep 20, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lucas Edelman | Director, Executive |
| Jeremy Dickinson Preston | Executive |
Issuer details
Industry: Other Technology (See others in industry)
Address:
Wework 50 60 Station Road
Cambridge, X0, CB1 2JH
Cambridge, X0, CB1 2JH